Close Menu

NEW YORK – Nucleai, a startup maker of a technology platform for precision oncology research and clinical decision support, said Tuesday that it has raised $6.5 million in the initial stage of a Series A funding round.

Swiss biopharmaceutical company Debiopharm led the investment, with participation from Vertex Ventures and Grove Ventures. As part of this investment, Debiopharm will collaborate with Nucleai on efforts to accelerate the discovery of biomarkers for oncology drug response.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.